Frank Dolan

FDA's Proposed Ban on Pharma Employees in Advisory Committees: Will It Truly Curb Conflicts of Interest?

FDA’s Proposed Ban on Pharma Employees in Advisory Committees: Will It Truly Curb Conflicts of Interest?

Frank Dolan April 22, 2025

Novo Nordisk Seeks FDA Approval for Oral Wegovy: A Game-Changer in the Weight Loss Market

Novo Nordisk Seeks FDA Approval for Oral Wegovy: A Game-Changer in the Weight Loss Market

Frank Dolan April 22, 2025

FDA's Game-Changing Move: Banning Pharma Employees from Advisory Committees to Ensure Drug Safety

FDA’s Game-Changing Move: Banning Pharma Employees from Advisory Committees to Ensure Drug Safety

Frank Dolan April 21, 2025

FDA Greenlights Dupixent for Hives Treatment While Rejecting Eylea's New Dosing Plan

FDA Greenlights Dupixent for Hives Treatment While Rejecting Eylea’s New Dosing Plan

Frank Dolan April 21, 2025

Navigating Biotech Turbulence: Trump’s Drug Pricing Order, Pfizer’s Setbacks & Seed Funding Decline

Navigating Biotech Turbulence: Trump’s Drug Pricing Order, Pfizer’s Setbacks & Seed Funding Decline

Frank Dolan April 19, 2025

Unlocking $30 Billion: How Alis Biosciences is Revolutionizing Biotech Investments and Maximizing Shareholder Value!

Unlocking $30 Billion: How Alis Biosciences is Revolutionizing Biotech Investments and Maximizing Shareholder Value!

Frank Dolan April 19, 2025

Breaking Barriers: VelaVigo's Second US Partnership Signals Booming China-US Biotech Collaborations

Breaking Barriers: VelaVigo’s Second US Partnership Signals Booming China-US Biotech Collaborations

Frank Dolan April 18, 2025

VelaVigo's Bold Move: How Chinese-US Biotech Collaborations are Revolutionizing Antibody Discovery

VelaVigo’s Bold Move: How Chinese-US Biotech Collaborations are Revolutionizing Antibody Discovery

Frank Dolan April 18, 2025

Eli Lilly's Orforglipron: A Game-Changer in the Fight Against Obesity and Diabetes with Promising Phase 3 Results

Eli Lilly’s Orforglipron: A Game-Changer in the Fight Against Obesity and Diabetes with Promising Phase 3 Results

Frank Dolan April 18, 2025

Blenrep: New Hope for Multiple Myeloma Patients as GSK Secures First Worldwide Approval in the UK

Blenrep: New Hope for Multiple Myeloma Patients as GSK Secures First Worldwide Approval in the UK

Frank Dolan April 17, 2025

Leadership Change at Charm Therapeutics: CEO Laksh Aithani Steps Down as Company Aims for AI-Driven Clinical Trials by 2026

Leadership Change at Charm Therapeutics: CEO Laksh Aithani Steps Down as Company Aims for AI-Driven Clinical Trials by 2026

Frank Dolan April 17, 2025

Bluebird Bio Faces Turbulent Times as Takeover Bid from Ayrmid Falls Flat: What Investors Need to Know

Bluebird Bio Faces Turbulent Times as Takeover Bid from Ayrmid Falls Flat: What Investors Need to Know

Frank Dolan April 17, 2025

Trump's New Drug Pricing Executive Order: A Mixed Bag for the Biopharma Industry

Trump’s New Drug Pricing Executive Order: A Mixed Bag for the Biopharma Industry

Frank Dolan April 16, 2025

GeneDx Acquires Fabric Genomics for $51 Million: A Game-Changer in Genetic Diagnostics

GeneDx Acquires Fabric Genomics for $51 Million: A Game-Changer in Genetic Diagnostics

Frank Dolan April 16, 2025

Johnson & Johnson's 2025 Earnings Outlook: Navigating Tariff Challenges and Investing in U.S. Manufacturing

Johnson & Johnson’s 2025 Earnings Outlook: Navigating Tariff Challenges and Investing in U.S. Manufacturing

Frank Dolan April 16, 2025

Revolutionizing Rare Disease Treatment: How FDA Guidelines are Transforming Orphan Drug Development with AI and Accelerated Approvals

Revolutionizing Rare Disease Treatment: How FDA Guidelines are Transforming Orphan Drug Development with AI and Accelerated Approvals

Frank Dolan April 16, 2025

Unlocking Precision Medicine: How QIAGEN's PGX Platform Enhances Pharmacogenomics with Evidence-Based Data

Unlocking Precision Medicine: How QIAGEN’s PGX Platform Enhances Pharmacogenomics with Evidence-Based Data

Frank Dolan April 16, 2025

Revolutionizing Heart Disease Treatment: Verve Therapeutics Unveils Promising Gene Editing Therapy Verve-102

Revolutionizing Heart Disease Treatment: Verve Therapeutics Unveils Promising Gene Editing Therapy Verve-102

Frank Dolan April 16, 2025

Pharmaceutical Execs Brace for Earnings Turbulence: How Tariffs and Regulatory Changes Could Impact Drug Markets

Pharmaceutical Execs Brace for Earnings Turbulence: How Tariffs and Regulatory Changes Could Impact Drug Markets

Frank Dolan April 16, 2025

Third Harmonic Bio to Liquidate: What This Means for Biotech Investors and Future Therapies

Third Harmonic Bio to Liquidate: What This Means for Biotech Investors and Future Therapies

Frank Dolan April 15, 2025

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Insitro Cuts Workforce by 22% Amidst Biotech Industry Challenges: What It Means for the Future of AI in Medicine

Insitro Cuts Workforce by 22% Amidst Biotech Industry Challenges: What It Means for the Future of AI in Medicine

Critical FDA Meeting: Shaping the Future of COVID-19 Vaccines for Fall and Winter 2023

Critical FDA Meeting: Shaping the Future of COVID-19 Vaccines for Fall and Winter 2023

FDA to Discuss COVID-19 Vaccine Boosters on May 22, 2025: What to Expect from Stricter Approvals and New Leadership

FDA to Discuss COVID-19 Vaccine Boosters on May 22, 2025: What to Expect from Stricter Approvals and New Leadership

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA